OncoGenex Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference

Labormitarbeiter bei der Arbeit. (Symbolbild). © sanjeri / E+ / Getty Images http://www.gettyimages.de

PR Newswire

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2015

BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2015 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2015 Healthcare Conference on Wednesday, November 18, 2015 at 2:15 p.m. EST at the New York Palace Hotel in New York City. The presentation will include an overview of the Phase 3 custirsen program, as well as the company's Phase 2 apatorsen development plans and timelines.

A live audio webcast can be accessed via http://www.veracast.com/webcasts/stifel/healthcare2015/05209772189.cfm or through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.

About OncoGenex
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncogenex-pharmaceuticals-to-present-at-the-stifel-2015-healthcare-conference-300172476.html

SOURCE OncoGenex Pharmaceuticals, Inc.

ARIVA.DE Börsen-Geflüster

Kurse

Achieve Life Sciences

4,50 $

+2,04%

Mehr Nachrichten zur Achieve Life Sciences Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.